Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 604 Carboplatin 374 Paclitaxel 283 Cisplatin 270 Gemcitabine 252 Pemetrexed 194 Bevacizumab 191 Docetaxel 186 Nivolumab 180 Injections 169 Cyclophosphamide 150 atezolizumab 139 Fluorouracil 134 Capecitabine 133 Oxaliplatin 132 Dexamethasone 128 durvalumab 113 Fulvestrant 113 130-nm albumin-bound paclitaxel 110 fludarabine 103 Cetuximab 100 Leucovorin 97 Rituximab 95 venetoclax 90 Lenalidomide 83 enzalutamide 77 Prednisone 77 Azacitidine 74 Irinotecan 73 Doxorubicin 72

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × dacomitinib × 1 year × Clear all

NCT04721106 2026-02-10

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Pfizer

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡